Гепатология и наука о поджелудочной железе

Liver stiffness predicts relapse after Direct acting antiviral therapy against chronic Hepatitis C Virus infection

Abstract

Ali Abdelrahman Sayed

Background & study aim: Assessment of fibrosis in chronic hepatitis has always been considered of utmost relevance for patient care in clinical hepatology. Over the last years, multiple non-invasive methods were used for diagnosis of hepaic fibrosis, including transient Elastography additionally to clinical and biochemical parameters or combinations of both methods. Serum markers and elastography are considered useful techniques for diagnosing severe liver fibrosis and cirrhosis and for excluding significant fibrosis in hepatitis C virus infected patients. Also, liver stiffness may help to foretell treatment response to antiviral therapy. We aimed to judge changes of Transient elastography values further as serum fibronectin and AST to platelet ratio index in patients (APRI) treated with sofosbuvir- based treatment regimen. Methods: this can be a follow-up study including 100 chronic HCV Egyptian patients treated with Sofosbuvir-based treatment regimen. Transient elastography values were recorded still as serum fibronectin and APRI were calculated at baseline and SVR12. Results: There was a big improvement of platelets counts, ALT and AST levels, which successively cause significant improvement in APRI scores at SVR12. Liver stiffness measurements were significantly lower at SVR12 (15.40�?��8.96 vs 8.82�?��4.74 kPa, P =0.000). There was significant decline in serum fibronectin from baseline to SVR 12 (524.14�?��237.61 vs 287.48�?��137.67, P=0.000). Key words: hepatitis C Virus, Liver stiffness, Transient Elastography and Fibronectin. Conclusion: Nonpegylated interferon (IFN) or pegylated IFN (PEGIFN) together with ribavirin (RBV) were the most drugs used for the management of HCV infection . the employment of the first-generation direct acting antivirals (DAAs) boceprevir and telaprevir with PEGIFN and RBV increased the general SVR rates to 68%-75% for naive patients and to 59%-88% for treatment-experienced patients, whether or not these regimens were used just for the treatment of genotype 1 HCV infection . Despite the positive effect of HCV infection eradication on patients??? prognosis, few data about liver cirrhosis/fibrosis regression are accessible